

DAFTAR PUSTAKA

1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borwithz MJ, Le Beau MM, *et al.* The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Stanford: Stanford University. *Am soci of hematol.* 2016; 127: 2391 - 2405.
2. Cancer Facts & Figures is an annual publication of the American Cancer Society, Atlanta, Georgia. 2017.
3. Ferlay J, Soerjomataram I, Dikshit R, Mathers C, Rebelo M, Parkin DM, *et al.* Cancer Incidence and Mortality Worldwide: Sources, methods and mayor pattern in Globocan 2012, France: Int J Cancer. 2015; 136(5): 359 - 386.
4. Fey MF, Buske C, Acute myeloblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Oxford: Oxford University. *Ann Oncol.* 2013; 25(6): 138 - 143.
5. Suzanna E, Tiarlan S, Rahayu PS, Shalmont G, Anwar E, Andalusia R, *et al.* Suplemen : registrasi kanker berbasis rumah sakit di rumah sakit kanker dharmais. pusat kanker nasional. Jakarta: Indo Journ of Can. 2012; 6(4):181 - 196.
6. Asputra H, peningkatan ekspresi FLT3 pada pasien leukemia mieloid akut serta korelasinya dengan jumlah leukosit dan *blast*, RSUP Dr. M. Djamil Padang, tesis. 2015; 56 - 57.
7. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Dombret H, *et al.* Diagnosis and management of AML in adult: 2017 ELN rekomendasi from an international expert panel, Jerman: ELN. 2017; 129(4): 424 - 447.
8. Yohe S, Molecular Genetic Markers in Acute Myeloid Leukemia, Department of Laboratory Medicine and Pathology, Divisions of Hematopathology and Molecular Genetic Pathology, United States. *J Clin Med,* 2015; 4: 460 - 478.
9. Box JK, Paquet N, Adams MN, Boucher D, Bolderson E, Richard DJ, *et al.* *Nucleophosmin*: from structure and function to disease development, Australia: BMC Molecular Biol. 2016; 17.
10. Verhaak RG, Goudswaard CS, Van PW, Bijl MA, Sander MA, Hugens W, *et al.* Mutations in *nucleophosmin (NPM1)* in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. European: NCBI, 2005; 106(12): 3747 - 54.
11. Gill H, Leung AY, Kwong YL, Molecular target therapy in acute myeloid leukemia, London: Future Oncology. 2016; 12(6): 1.

12. Pasqualucci L, Liso A, Marteli MP, Bolii N, Pacini R, Tabarrini A, *et al.* Mutated *nucleophosmin* detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Italy. *Blood*. 2006; 108(13): 4146 - 4155.
13. Ottone T, Ammatuna E, Lavorgna S, Noguera NI, Buccisano F, Venditti A, *et al.* An allele-specific *qRT-PCR* assay to detect mutation of the *nucleophosmin-1* gene in acute myeloid leukemia. Italia: *J Mol Diagn*. 2008; 10(3): 212 - 216.
14. Chou W, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, *et al.* *Nucleophosmin* mutations in de novo acute myeloid leukemia: The age-dependent incidences and the stability during disease evolution. Taiwan: *Cancer Research*. 2006: 3310 - 3316.
15. Yan L, Chen S, Liang J, Feng Y, Cen J, Dia J, *et al.* Analysis of *NPM1* gene mutations in Chinese adults with acute myeloid leukemia. Chinese: *Int J Hematol*. 2007; 86(2): 143 - 146.
16. Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD, *et al.* Biological and clinical consequences of *NPM1* mutations in AML, USA: *Leukemia*, 2017; 31(4): 798 - 807.
17. Davoidi M, Davoidi P, *Nucleophosmin-1* expression in acute myeloid leukemia, Iran: *RCM*. 2015; 2(4): 209 - 211.
18. Yacoub A & Mahalwar G, Dentist to Oncologist; Gingival Hyperplasia in AML Accompanied By Periodontal Infection-Case Report, Washington DC, *ASH*. 2016; 128: 5187.
19. Hasan S, Khan, NI, Reddy LB, Leukemic gingival enlargement : Report of arare case with review of literature, India: *Int J. Appl Basic Med Des*. 2015; 5(1): 65 - 67.
20. Jo SY, Park SH, Kim IS, Yi J, Kim HH, Chang CL, *et al.* Corelation of *NPM1* mutation with clinical status and outcomes in acute myeloid leukemia patient, Korea: *Ann Lab Med*. 2016; 36(5): 399 - 404.
21. Quan J, Gao YJ, Yang ZL, Chen H, Xian JR, Zhang SS, *et al.* Quantitative Detection of Circulating *Nucleophosmin* Mutations DNA in the Plasma of Patients with Acute Myeloid Leukemia, China: *Int J Med Sci*. 2015; 12(1): 17 - 22.
22. Akbar DF. Deteksi mutasi *Nucleophosmin* (*NPM1*) pada pasien Leukemia Mieloblastik Akut (LMA) dewasa di Rumah Sakit Cipto Mangunkusumo (RSCM) dan Rumah Sakit Kanker Dharmais (RSKD). Universitas Indonesia Jakarta: Tesis. 2013.
23. Dohnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, *et al.* Acute Myeloid Leukemia, Version 3.2017, NCCN linical Practice Guidelines in Oncology. *J Natl Comp Canc Netw*. 2017; 15(7): 926 - 957.

24. Kurnianda J. Leukemia mieloblastik akut. Dalam: Buku Ajar Ilmu Penyakit Dalam. Edisi kelima, jilid II, editor Sudoyo A dkk. Interna Publishing, Jakarta. 2009: 716 - 722.
25. Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, *et al.* De novo acute myeloid leukemia with 20-29% *blast* is less aggressive than acute myeloid leukemia with $\geq 30\%$ blast in older adult; a bone marrow pathology group study. USA: Am J Hematol, 2014; 89(11): 193 - 199.
26. Zuo Z. Molecular diagnostics of acute myeloid leukemia. Review Diagnostic Histopathology, USA: AJH, 2009; 531 - 9.
27. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner H, Diagnosis and Management of AML in Adult: 2017 ELN Recommendations from an International Expert Panel. USA: ELN, 2017; 11: 55.
28. Yohe S, Molecular Genetic Markers in Acute Myeloid Leukemia, Department of Laboratory Medicine and Pathology, Divisions of Hematopathology and Molecular Genetic Pathology, J Clin Med, 2015; 4(3): 460 - 478.
29. Abdel WO & Zuckerman. Molecular genetics of acute myeloid leukemia: Clinical implications and opportunities for integrating genomics into clinical practice. Leukemia and human oncology, memorial sloan-kettering cancer centre, New York, USA. 2012: 39 - 42.
30. Mikael S. NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling, USA: Bio Res Inter. 2011: 1 - 16.
31. Grisendi S, Mecucci C, Falini B, Pandolfi PP. *Nucleophosmin* and cancer. Nature Reviews. 2006: 493 - 505.
32. Falini B, Nicoletti I, Bolli N, Marteli MF, Liso A, Garelli P, *et al.* Translocations and mutations involving the *nucleophosmin* (*NPM1*) gene in lymphomas and leukemias. Haematologica. 2007; 92: 519 - 532.
33. Falini B, Nicoletti I, Bolli N, Marteli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated *nucleophosmin* (*NPMc+AML*): biological and clinical features. Italy: Blood. 2007; 109(3): 874 - 85.
34. Akl H, Gawish H, Taleb F, *Nucleophosmin* (*NPM1*) and FMS-like tyrosine kinase 3 (*FLT3*) mutations in acute myeloid leukaemia with a normal karyotype: frequency and prognostic significance, ESH, Yunani. 2012; 37(4): 200 - 206.
35. Meng CY, Noor PJ, Ismail Azli, Ahid MF, Zakaria Z, Cytogenetic Profile of de novo Acute Myeloid Leukemia Patients in Malaysia, Int J Biomed Sci. 2013; 9(1): 26 - 32.

36. Ohnishi H, Imataki O, Kawachi Y, Ide M, Kawakami K, Waki M, *et al.* Age is an independent adverse prognostic factor for overall survival in acute myeloid leukemia in Japan, *World J Hematol.* 2014. 3(3): 105 - 114.
37. Abuhelwa Z, Al Shaher Q, Taha S, Ayoub K, Amer R, Characteristics of De Novo Acute Myeloid Leukemia Patients in Palestine: Experience of An-Najah National University Hospital, *APJCP, Palestine.* 2017; 18 (9): 2459 - 2464.
38. Sitelbanat HO, Kordofani AA, Osman IM, Musa OH, Altayb HN, Bahaeldin KE, Prevalence of the different FAB sub type of Acute Myeloid Leukemia related to hematological parameters in Sudanese, *JHBD, Sudan.* 2017; 3: 2455 - 7641.
39. Khera R, Ahmed F, Mundada MC, Devi SG, Murthy SS, Lavanya N, *et al.* Multiplex Approach in Classification, Diagnosis, and Prognostication in Acute Myeloid Leukemia: An Experience from Tertiary Cancer Center in South India, *IJMPO.* 2017; 38 (3): 266 - 272.
40. Alrajeh EI, Abalkhail H, Hkhalil SH, Cytogenetics and Molecular Markers of Acute Myeloid Leukemia from a Tertiary Care in Saudi Arabia, *JAHA.* 2017; 8 (2): 68 - 74.
41. Jongen LM, Grob T, Hanekamp D, Kavelaars FG, Alhinai A, Zailemaker A, *et al.* Molecular Minimal Residual Disease in Acute Myeloid Leukemia, *NEJM.* 2018; 378: 1189 - 1199.
42. Zidan M, Shaaban H, Ghannam DE, Prognostic Impact of *Nucleophosmin-1 (NPM1)* Gene Mutations in Egyptian Acute Myeloid Leukemia Patients, *Turk J Hematol, Mesir.* 2013; 30: 129 - 136.
43. Yoshida H, Horai M, Masunishi M, Hata T, Nogami T, Ayuse T, *et al.* Management of gingival hyperplasia associated with sore mucositis in an acute leukemia patient, *Case Report, Japan.* 2016; 60(3): 129 - 133.
44. Chowdhri K, Tandon S, Lamba AK, Faraz F. Leukemic gingival enlargement: A case report and review of literature. *J Oral Maxillofac Pathol.* 2018; 22(1): 77 - 81.
45. Misirlioglu M, Adisen MZ, Yilmaz. Diagnosis of acute myeloid leukemia in a dental hospital; report of case with severe gingival hypertrophy, *Case Report, Turkey.* 2014.
46. Dev JN, Madhuri SV, Buggapati L, Kotaiah T, Ahmed MA, Leukemic Gingival Enlargement - A Role Of Periodontist In Early Diagnosis And Prompt Referral: A Case Report, *JADMS.* 2016.
47. Luo J, Qi C, Xu W, Reid SK, Brandwein J, Chang H, Cytoplasmic Expression of *Nucleophosmin* Accurately Predicts Mutation in the *Nucleophosmin* Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype, *ASCP.* 2010: 34 - 40.

48. Liu Y, He P, Liu F, Shi L, Zhu H, Zhao J, *et al*, Prognostic significance of *NPM1* mutations in acute myeloid leukemia: A meta-analysis, *Mol Clin Oncol*, China. 2014; 2(2): 275 - 281.
49. Rastogi P, Naseem S, Varma N, Varma S, *Nucleophosmin* mutation in de-novo acute myeloid leukemia, *Asia Pac J Clin Oncol*. India. 2015; 12.
50. Jo SY, Park SH, Kim IS, Yi J, Kim HH, Chang CL, *et al*, Correlation of *NPM1* Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated *NPM1*, *Ann Lab Med*, Korea. 2016; 36(5): 399 - 404.
51. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, *et al*, Acute myeloid leukemia with mutated *nucleophosmin (NPM1)*: is it a distinct entity?, *ASH*, Jerman. 2011; 117: 1109 - 1120.
52. Dhahir EK, Dhahi MA, High Frequency of *Nucleophosmin* Mutations in Thirty Two Iraqi Adult Patients with Acute Myeloid Leukemia, *IJAST*, Iraq. 2012; 2(5): 97 - 105.
53. Leibundgut EO, Porret NA, Muggli MB, Baumgartner H, Dahlhaus M, Baerlocher GM, Rapid and highly specific screening for *NPM1* mutations in acute myeloid leukemia, *Ann Hematol*, Berlin. 2013; 92(2): 173 - 177.
54. Kazem AH, Mikhael IL, Ghanem AM, Cytoplasmic *nucleophosmin (cNPM)* in acute myeloid leukemia: Relation to disease characteristics, *AJM*, Kairo. 2011; 225 - 235.
55. Laxmi GD, Mubeen K, Suman B, Acute Myelomonocytic Leukemia with Gingival Enlargement: A Case Report, *IJOMP*, India. 2014: 31 - 34.
56. Shamimul H, Nabeel IK, Bhaskar LR. Leukemia gingival enlargement: report of a rare case with review of literature. *IJAB Med Res*. 2015: 65 - 67.
57. Guan G, Firth N, Oral manifestation as an early clinical sign of acute myeloid leukemia: a case report, *Australian Dental J*. 2015; 60: 123 - 127.
58. Chang F, Shamsi TS, Waryah AM, Clinical and Hematological Profile of Acute Myeloid Leukemia (AML) Patients in Sindh, *J Hematol Thrombo*, Pakistan. 2016; 4: 239.